Cargando…
Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports
BACKGROUND: Polypoidal choroidal vasculopathy (PCV) consists of polyps that potentially cause massive subretinal hemorrhage and their branching vascular network (BVN) of feeder vessels. Although conventional indocyanine green angiography (IA) has shown anti-vascular endothelial growth factor (VEGF)...
Autores principales: | Iesato, Yasuhiro, Tanaka, Masaaki, Murata, Masako, Kitahara, Junya, Hirano, Takao, Kurenuma, Taihei, Yoshida, Noriko, Murata, Toshinori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215629/ https://www.ncbi.nlm.nih.gov/pubmed/30390650 http://dx.doi.org/10.1186/s12886-018-0952-6 |
Ejemplares similares
-
Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
por: Nemoto, Rei, et al.
Publicado: (2012) -
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
por: Gu, Xiaoya, et al.
Publicado: (2019) -
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
por: Wong, Ian Y., et al.
Publicado: (2015) -
Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017) -
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)